LetterCannabidiol in dystonic movement disorders
References (6)
- et al.
Tetrahydrocannabidiol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease
Marijuana as a therapeutic agent for muscle spasm or spasticity
Psychosomatics
(1980)- et al.
GABA-ergic mediation in the inhibition of hippocampal turnover rate elicited by delta-9-tetrahydrocannabidiol
Neuropharmacology
(1979)
Cited by (26)
Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials
2016, Basal GangliaCitation Excerpt :There have not been any neuropathologic or imaging studies of cannabinoid receptor levels in individuals with dystonia. The anti-dystonic effects reported in an animal model and several case reports in individuals with focal or generalized dystonia suggest that cannabinoid treatment may be beneficial in individuals with dystonia [62–69]. Only three clinical studies have looked at cannabinoid agonist treatment in dystonia to date.
Phytocannabinoids as novel therapeutic agents in CNS disorders
2012, Pharmacology and TherapeuticsCitation Excerpt :However, daily treatment with Δ9-THC (10 mg/kg over 8 weeks) reportedly had no effect on motor deterioration in a mouse transgenic model of HD (Dowie et al., 2010). A small clinical trial following daily CBD (300–600 mg) treatment demonstrated an improvement in HD symptoms in 1 of 4 participants (Sandyk et al., 1986); however, a double-blind randomised placebo-controlled crossover trial in 15 HD patients showed no significant effect of CBD (10 mg/kg/day, 6 weeks) on chorea severity (Consroe et al., 1991). More recently, a randomised, double-blind crossover placebo-controlled trial with 37 patients investigating the effects of the synthetic Δ9-THC analogue nabilone (1–2 mg) showed no effect on the primary outcome (the Unified Huntington's Disease Rating Scale), but some evidence of improvement in chorea and neuropsychiatric outcomes (Curtis et al., 2009).
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats
2004, NeuropharmacologyCitation Excerpt :Some cannabis extracts are also rich in cannabidiol (CBD), which is chemically similar to Δ9-THC but devoid of any psychoactivity (Pertwee, 1988,2004). CBD is anxiolytic (Musty, 1984; Guimarães et al., 1990; Zuardi et al., 1982), anticonvulsant (Karler and Turkanis, 1981; Wallace et al., 2001), neuroprotective (Hampson et al., 1998), anti-inflammatory (Sofia et al., 1973; Evans et al., 1987), affects growth and proliferation of cancer cells (Jacobsson et al., 2000) and improves motor function in dystonic patients (Sandyk et al., 1986). These data suggest that CBD has some effects in common with Δ9-THC, but detailed behavioral testing of synthetic CBD- or CBD-rich cannabis extracts on memory and learning has not been reported.
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia
2002, European Journal of Pharmacology(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters
1994, European Journal of PharmacologyDrugs of abuse
1988, Side Effects of Drugs Annual